Abstract
The success of tyrosine kinase inhibitors in treating chronic myeloid leukemia highlights the potential of targeting oncogenic kinases with small molecules. By using drug activity profiles and individual patient genotypes, one can guide personalized therapy selection for patients with resistance.
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Drug Resistance, Neoplasm
-
Fusion Proteins, bcr-abl / antagonists & inhibitors
-
Fusion Proteins, bcr-abl / genetics
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
-
Molecular Targeted Therapy
-
Mutation
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Kinase Inhibitors / therapeutic use
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Fusion Proteins, bcr-abl